Quarterly ResultAug 13, 2026, 04:21 PM
Invivyd Raises Going Concern Doubt; Q2 Net Loss $44.4M
AI Summary
Invivyd, Inc. reported a net loss of $(44.4) million for the second quarter of 2026, significantly wider than the $(14.7) million loss in the same period last year, despite product revenue increasing to $14.3 million. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. Research and development and selling, general and administrative expenses saw significant increases, while cash and cash equivalents declined to $160.1 million.
Key Highlights
- Invivyd disclosed substantial doubt about its ability to continue as a going concern.
- Net loss for Q2 2026 was $(44.4) million, compared to $(14.7) million in Q2 2025.
- Product revenue for Q2 2026 increased to $14.3 million from $11.8 million in Q2 2025.
- Research and development expenses surged to $29.4 million in Q2 2026 from $9.6 million in Q2 2025.
- Cash and cash equivalents decreased to $160.1 million at June 30, 2026, from $226.7 million at Dec 31, 2025.
- PEMGARDA EUA is set to terminate on June 29, 2027, after a 12-month transition period.
- Completed enrollment for VYD2311 DECLARATION and LIBERTY clinical trials.
Price Impact
More from IVVD